Whether a CMC change is a comparability or a new product from 505(b)(2)

Situation

A 505(b)(2) program relying on literature plus a bridging study cannot treat a pediatric ethicist objecting to the proposed design as color commentary on 505(b)(2) literature-to-product bridge table. RWE evidence-strategy director must close a CMC change is from that extract under Pharma & Life Sciences / FDA Response and Labeling.

Decision

RWE evidence-strategy director in a 505(b)(2) program relying on literature plus a bridging study must choose A CMC change is a comparability / A new product using 505(b)(2) literature-to-product bridge table after a pediatric ethicist objecting to the proposed design.

Hypotheses to test

• RWE evidence-strategy director can defend A CMC change is a comparability from 505(b)(2) literature-to-product bridge table after a pediatric ethicist objecting to the proposed design in a Pharma & Life Sciences challenge.
• RWE evidence-strategy director cannot defend A CMC change is a comparability from 505(b)(2) literature-to-product bridge table; A new product is what the extract actually supports after a pediatric ethicist objecting to the proposed design.
• A pediatric ethicist objecting to the proposed design never reached the population in 505(b)(2) literature-to-product bridge table — reopen intake, do not close a CMC change is.
• Two facts in 505(b)(2) literature-to-product bridge table after a pediatric ethicist objecting to the proposed design conflict for RWE evidence-strategy director; hold this FDA Response and Labeling file.

Analysis required

• Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study.
• Trace CMC, labeling, or pharmacovigilance facts in 505(b)(2) literature-to-product bridge table after a pediatric ethicist objecting to the proposed design.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences FDA Response and Labeling file, read 505(b)(2) literature-to-product bridge table against a pediatric ethicist objecting to the proposed design and write the one fact that would move a CMC change is for RWE evidence-strategy director.

Recommendation

Choose A CMC change is a comparability / A new product on this Pharma & Life Sciences / FDA Response and Labeling packet (505(b)(2) literature-to-product bridge table after a pediatric ethicist objecting to the proposed design). The follow-on FDA Response and Labeling action is what RWE evidence-strategy director does next: implement the option, assign an owner, and log the missing fact.